[HTML][HTML] Drug resistance and combating drug resistance in cancer
Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
[HTML][HTML] Kinase-targeted cancer therapies: progress, challenges and future directions
KS Bhullar, NO Lagarón, EM McGowan, I Parmar… - Molecular cancer, 2018 - Springer
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …
Covalent inhibition in drug discovery
Although covalent inhibitors have been used as therapeutics for more than a century, there
has been general resistance in the pharmaceutical industry against their further …
has been general resistance in the pharmaceutical industry against their further …
Osimertinib: first global approval
SL Greig - Drugs, 2016 - Springer
Abstract Osimertinib (Tagrisso™, AZD9291) is an oral, third-generation epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca …
factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca …
[HTML][HTML] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
J Hou, H Li, S Ma, Z He, S Yang, L Hao, H Zhou… - Biomarker …, 2022 - Springer
Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
[HTML][HTML] The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Methods One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was …
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was …
Clinical validity of saliva and novel technology for cancer detection
KE Kaczor-Urbanowicz, F Wei, SL Rao, J Kim… - … et Biophysica Acta (BBA …, 2019 - Elsevier
Cancer, a local disease at an early stage, systemically evolves as it progresses by triggering
alterations in surrounding microenvironment, disturbing immune surveillance and further …
alterations in surrounding microenvironment, disturbing immune surveillance and further …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for non–small-cell lung cancer patients with leptomeningeal carcinomatosis
BC Liao, JH Lee, CC Lin, YF Chen, CH Chang… - Journal of Thoracic …, 2015 - Elsevier
Background Leptomeningeal carcinomatosis (LC) is a detrimental complication of patients
with non–small-cell lung cancer (NSCLC). The effect of epidermal growth factor receptor …
with non–small-cell lung cancer (NSCLC). The effect of epidermal growth factor receptor …
[HTML][HTML] Epigenetic alterations and inflammation as emerging use for the advancement of treatment in non-small cell lung cancer
Lung cancer remains one of the most common malignancies in the world. Nowadays, the
most common lung cancer is non-small cell lung cancer (NSCLC), namely …
most common lung cancer is non-small cell lung cancer (NSCLC), namely …
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
Abstract EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs.
Third-generation EGFR TKIs against the T790M mutation have been in active clinical …
Third-generation EGFR TKIs against the T790M mutation have been in active clinical …